Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Non-infectious uveitis requires effective long-term management.
• Biologic therapies, such as infliximab, are crucial for controlling inflammatory eye diseases.
• Biosimilars offer a potentially cost-effective alternative to originator biologics.

Purpose of the Study:

• To evaluate the recurrence rate of uveitis in patients treated with the biosimilar infliximab-dyyb.
• To assess the efficacy of infliximab-dyyb in maintaining disease control in non-infectious uveitis.

Main Methods:

• A retrospective case series reviewed 14 patients with non-infectious uveitis treated between 2016-2022.
• Data included demographics, diagnosis, prior infliximab use, and disease activity.
• Patients were either switched from originator infliximab or initiated directly on infliximab-dyyb.

Main Results:

• None of the 8 patients switched to infliximab-dyyb experienced recurrence.
• Five of the 6 patients initiated on infliximab-dyyb achieved disease quiescence.
• Dosing and administration schedules remained consistent between originator and biosimilar infliximab.

Conclusions:

• Infliximab-dyyb demonstrates efficacy in controlling non-infectious uveitis.
• The biosimilar appears to be a viable therapeutic option for maintaining remission.
• Further studies can explore long-term outcomes and comparative effectiveness.